Loading view.
breast
Learn about the Homologous Recombination Deficiency service
Online , United KingdomNICE guidelines state that some patients with ovarian, breast & prostate cancer should receive genomic testing for Homologous Recombination Deficiency to identify for PARP inhibitors treatment eligibility. The South East Genomic Medicine Service has launched a new Homologous Recombination Deficiency (HRD) service for all NHS colleagues working within cancer across the South East. Join our […]